Stay updated on Propranolol and Pembrolizumab in Melanoma Clinical Trial
Sign up to get notified when there's something new on the Propranolol and Pembrolizumab in Melanoma Clinical Trial page.

Latest updates to the Propranolol and Pembrolizumab in Melanoma Clinical Trial page
- Check6 days agoChange DetectedThe footer revision identifier changes from v3.7.1 to v3.7.2, while the page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check13 days agoChange DetectedThe ClinicalTrials.gov footer revision changed from v3.7.0 to v3.7.1; the study record still displays a 403 error.SummaryDifference0.2%

- Check20 days agoNo Change Detected
- Check34 days agoChange DetectedThe page now displays a 403 Forbidden error, replacing the study record and site navigation with an access-denied screen, which prevents viewing the trial details.SummaryDifference19%

- Check55 days agoChange DetectedThe page now shows Revision: v3.6.6, indicating a backend/template update. This change reflects a version bump rather than modifications to study details or data.SummaryDifference0.1%

- Check76 days agoChange DetectedRevision label updated to v3.6.5 on the page. This indicates a minor maintenance update to the study page's content or metadata.SummaryDifference0.1%

- Check90 days agoChange DetectedThe study record revision identifier was updated from v3.6.3 to v3.6.4, indicating a small backend/content management update.SummaryDifference0.1%

Stay in the know with updates to Propranolol and Pembrolizumab in Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Propranolol and Pembrolizumab in Melanoma Clinical Trial page.